Evotec SE (EVO) Total Non-Current Liabilities (2009 - 2026)
Evotec SE (EVO) reported Total Non-Current Liabilities of $605063.6 for Q1 2026, down 14.89% on a YoY basis from $710906.6 in Q1 2025, and down 2.32% sequentially from $619465.5 in Q4 2025.
Evotec SE (EVO) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Total Non-Current Liabilities data on file, last reported at $605063.6 in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 14.89% year-over-year to $605063.6; the trailing twelve-month figure through Mar 2026 stood at $605063.6 (down 14.89% YoY), and the FY2025 full-year result was $619465.5, down 99.91% from the prior year.
- Total Non-Current Liabilities slipped to $605063.6 in Q1 2026, from $619465.5 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $747.2 million in Q4 2022 to a low of $404.41 in Q2 2022.
- A 5-year average of $177.4 million and a median of $699141.1 in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities climbed 22.55% in 2022 and slumped 99.91% in 2025, its largest moves.
- Tracing EVO's Total Non-Current Liabilities over 5 years: stood at $747.2 million in 2022, then slipped by 3.81% to $718.7 million in 2023, then fell by 8.5% to $657.6 million in 2024, then tumbled by 99.91% to $619465.5 in 2025, then dropped by 2.32% to $605063.6 in 2026.
- Business Quant data shows EVO's Total Non-Current Liabilities at $605063.6 in Q1 2026, $619465.5 in Q4 2025, and $699208.3 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 605,063.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 605,063.60 |
| Dec 31, 2025 | 619,465.55 |
| Sep 30, 2025 | 699,208.34 |
| Jun 30, 2025 | 655,728.40 |
| Mar 31, 2025 | 710,906.63 |
| Dec 31, 2024 | 657.61 Mn |
| Sep 30, 2024 | 756,366.83 |
| Dec 31, 2023 | 718.71 Mn |
| Dec 31, 2022 | 747.19 Mn |
| Sep 30, 2022 | 699,073.90 |
| Jun 30, 2022 | 404.41 |
| Mar 31, 2022 | 601,058.99 |
| Dec 31, 2021 | 609.69 Mn |
| Sep 30, 2021 | 614,870.98 |
| Dec 31, 2020 | 631.22 Mn |
| Sep 30, 2010 | 23,121.53 |
| Jun 30, 2010 | 8,710.96 |
| Mar 31, 2010 | 10.40 |
| Dec 31, 2009 | 12,798.86 |
| Aug 31, 2009 | -93.19 |